MONTREAL, Feb. 1, 2013 /CNW/ - Valeant Pharmaceuticals International, Inc.
(NYSE: VRX and TSX: VRX) today announced the completion of its acquisition of
Natur Produkt International, JSC, a specialty pharmaceutical company in
Russia, for approximately $163 million, plus adjustments for net debt and
working capital. Natur Produkt has a significant presence in the
over-the-counter (OTC) segment in several categories marketed under the
umbrella brand, Natur Produkt. Key brands include AntiGrippin, a leading
cough and cold remedy, Anti Angin, Sage and Eucaplyptus MA brand names,
leading sore throat remedies.
About Valeant Pharmaceuticals International, Inc.
Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational
specialty pharmaceutical company that develops, manufactures and markets a
broad range of pharmaceutical products primarily in the areas of dermatology,
neurology and branded generics. More information about Valeant
Pharmaceuticals International, Inc. can be found at www.valeant.com.
Contact Information: Laurie W. Little 949-461-6002 email@example.com
PRN Photo Desk, firstname.lastname@example.org
SOURCE: Valeant Pharmaceuticals International, Inc.
To view this news release in HTML formatting, please use the following URL:
CO: Valeant Pharmaceuticals International, Inc.
NI: HEA MTC MNA
-0- Feb/01/2013 13:50 GMT
Press spacebar to pause and continue. Press esc to stop.